Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075271 | 0.89 | PDE10A (0.52) | PDE10A | |
| SCHEMBL26075411 | 0.87 | HMOX1 (0.42) | ALOX5APFEN1TP53 | |
| SCHEMBL23590136 | 0.87 | DHODH (0.49) | PDE10AALOX5APFEN1TP53 | |
| SCHEMBL26075875 | 0.86 | PDE10A (0.44) | PDE10AALOX5APFEN1PDE3ATP53 | |
| SCHEMBL26075292 | 0.85 | FEN1 (0.41) | ALOX5APFEN1MAPTTP53 | |
| SCHEMBL26075379 | 0.84 | PTGS2 (0.44) | ALOX5APFEN1MAPTTP53 | |
| SCHEMBL26075395 | 0.83 | ACP1 (0.39) | PDE10AALOX5APFEN1MAPT | |
| SCHEMBL26075438 | 0.83 | ACP1 (0.39) | PDE10AALOX5APFEN1 | |
| SCHEMBL26075920 | 0.80 | ACP1 (0.44) | ALOX5APFEN1MAPT | |
| SCHEMBL26075973 | 0.80 | FEN1 (0.39) | ALOX5APFEN1TP53PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | PDE10A 3462/4885ALOX5AP 821/4885FEN1 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.